Omadacycline Tosylate is an active aminomethylcycline antibiotic belonging to the Tetracycline class. It can be used to research acute bacterial skin and skin-structure infections, community-acquired pneumonia and urinary tract infections. The compound was approved by the US FDA in 2018. It was invented at Tufts University School of Medicine and developed by Paratek Pharmaceuticals (Boston, MA) with the aim of identifying novel minocycline derivatives at the C-9 position.
